Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]

Trial Profile

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms ELLACTO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 04 Jan 2019 Planned End Date changed from 31 Dec 2018 to 22 Feb 2019.
    • 04 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 19 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 9 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top